Y. Kawashima

发表

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Y. Ishikawa, M. Nishio, H. Ninomiya, 2019, Internal medicine.

Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)

Y. Tsuchiya, M. Nishio, R. Ariyasu, 2020, Haigan.

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.

M. Seike, M. Okada, S. Morita, 2021, The Lancet. Respiratory medicine.

A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung

S. Yamanda, J. Akahira, S. Sugawara, 2019, JMA Journal.

Phase II study of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan Lung Cancer Group 1101 (NJLCG1101)

T. Harada, S. Sugawara, A. Inoue, 2021 .

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)

M. Nishio, A. Horiike, Takahiro Yoshizawa, 2022, Thoracic cancer.

Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers

A. Niida, J. Sugisaka, S. Yamanda, 2021, PLoS ONE.

Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.

Kunihiko Kobayashi, M. Maemondo, T. Nukiwa, 2013 .

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib

M. Nishio, R. Ariyasu, A. Horiike, 2017, Anti-cancer drugs.

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)

M. Nishio, A. Horiike, N. Yanagitani, 2022, Thoracic cancer.

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

H. Ono, J. Sugisaka, S. Yamanda, 2021, Cancer medicine.

Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

T. Harada, T. Nakagawa, S. Sugawara, 2020, International Journal of Clinical Oncology.

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

H. Ono, J. Sugisaka, S. Yamanda, 2019, JMA journal.

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

J. Sugisaka, S. Yamanda, S. Sugawara, 2019, The oncologist.

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

J. Sugisaka, S. Yamanda, S. Sugawara, 2019, JAMA oncology.

Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs

Kunihiko Kobayashi, T. Nukiwa, T. Kikuchi, 2018, Anticancer Research.

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.

J. Sugisaka, S. Yamanda, S. Sugawara, 2018, The oncologist.

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)

K. Azuma, I. Okamoto, T. Kurata, 2022, Thoracic cancer.

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630

Yukiko Nakamura, M. Seike, T. Harada, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.

Y. Ishikawa, M. Nishio, H. Ninomiya, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.

A. Gemma, M. Nishio, R. Ariyasu, 2019, Lung cancer.

Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo).

M. Nishio, R. Ariyasu, A. Horiike, 2017 .

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

Makoto Nishino, R. Ariyasu, A. Horiike, 2023, Cancer Chemotherapy and Pharmacology.

A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202

N. Yoshimura, T. Harada, E. Miyauchi, 2023, Oncology letters.

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

S. Oizumi, M. Maemondo, T. Nukiwa, 2014, Respiratory investigation.

Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world

J. Sugisaka, S. Yamanda, S. Sugawara, 2019, Annals of Oncology.

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

J. Sugisaka, S. Yamanda, S. Sugawara, 2020 .

Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.

J. Sugisaka, S. Yamanda, S. Sugawara, 2023, Thoracic cancer.

P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Naïve Squamous Cell Lung Cancer: NJLCG1302

T. Harada, T. Nakagawa, S. Sugawara, 2019, Journal of Thoracic Oncology.

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma

A. Tsuya, Y. Namba, M. Toda, 2023, JTO clinical and research reports.

Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

T. Harada, S. Sugawara, A. Inoue, 2023, Thoracic cancer.

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome

J. Sugisaka, S. Yamanda, S. Sugawara, 2024, Cancer reports.

Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.

R. Toyozawa, T. Tokito, Y. Shiraishi, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.